Kandrozid (Candesartan Cilexetil)

Candesartan cilexetil selectively blocks AT1 receptors for angiotensin II, preventing vasoconstriction, aldosterone release, and sympathetic activation. This results in vasodilation, reduced sodium and water retention, and lower blood pressure, while also protecting the heart and kidneys from harmful remodeling.

The appropriate dose of Kandrozid is determined by the prescribing healthcare professional based on the patient’s medical condition, response to therapy, and renal function. Dosage adjustments are individualized, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

Safety of candesartan cilexetil in pregnancy has not been established, and it is generally avoided because of potential fetal toxicity. Limited data are available for breastfeeding; therefore, the benefits and risks should be carefully evaluated by a healthcare provider before use.

To order Kandrozid, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and import documentation.

Kandrozid belongs to the ARB class, offering similar blood‑pressure control to ACE inhibitors but with a lower incidence of cough and angioedema. Compared with calcium‑channel blockers, it provides additional renal protection in diabetic patients, making it a preferred option for certain comorbidities.

Kandrozid should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat, and direct sunlight to maintain stability and potency throughout the shelf life.

Kandrozid is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious risks include angioedema, severe hyperkalemia, acute renal failure, and symptomatic hypotension. Patients should be educated to seek immediate medical attention if they experience swelling of the face or throat, rapid heartbeat, severe dizziness, or sudden loss of kidney function.

Kandrozid is contraindicated in individuals with known hypersensitivity to candesartan or any ARB component. It should also be avoided in patients with severe hepatic impairment, pregnant women, and those taking certain medications that may cause dangerous interactions, such as ACE inhibitors or potassium‑sparing diuretics.